Page 3«..2345..1020..»

Gergis Explains the Differences Between Acute and Chronic GVHD – Targeted Oncology

By daniellenierenberg

Usama Gergis, MD, MBA Professor of Oncology Director, Bone Marrow Transplant and Immune Cellular Therapy Sidney Kimmel Cancer Center Thomas Jefferson University Hospital Philadelphia, PA, reviewed that difference in acute and chronic graft-versus-host disease (GVHD) and the treatment available for each.

Targeted OncologyTM: How would you treat a patient with GvHD in the second line?

GERGIS: If you [have a patient with] second-line acute GVHD, your answer should be ruxolitinib [Jakafi] because its the only drug that has been tried in phase 3 trials. If you get a [case of] chronic GVHD, your answer should be ibrutinib [Imbruvica].

What is the efficacy of peripheral blood stem cells (PBSC) versus bone marrow from unrelated donors in patients with acute and chronic GvHD?

[Results from] a phase 3 study of bone marrow versus stem cells for unrelated donors [showed] the acute GVHD population [cumulative incidence] was the same between both.1 For the chronic population, the bone marrow did better [PBSC 53% vs bone marrow 41%; P = .01]. This was published almost 8 years ago, [and it] was reported almost 10 years ago, but we still use stem cells.

This has not changed practices, and the reasons are, number 1, there was more primary graft failure on the bone marrow than the PBSC, and number 2, its pretty involved to do bone marrow harvest, although I have done it for 15 years, at least a few every month.

The benefit of bone marrow versus PBSCand this benefit was only studied in unrelated donors, not in matched related donorswas seen across all organs affected with chronic GVHD except lungs, [gut, and serosa].2 So, there was no real benefit in the lungs.

Can you explain the difference between acute and chronic GvHD?

Chronic GVHD is more complicated and involved than acute GVHD. In acute, you have the skin, gastrointestinal organs, and the liver [that may be affected]. Thats it. In chronic, all the patients other organs can be affected. The patients weight can be affected. [Chronic GVHD is] more debilitating over a long time and [can] go unrecognized for a while. [If a patient is] experiencing acute GVHD, you see them twice a week, whereas if the patient has chronic GVHD, you probably see them once a month. So you can see a very stark change in your patients within that month if they lose 10% of their body weight and they already lost a lot of weight in the period right after [transplantation], so that can be obvious to you.

[In my institution], we have the GVHD clinic where we [grade the patient based on] studying the degree of fibrosis, how many organs are affected, the patients range of motion, and the degrees in range of motion. We do frequent pulmonary function tests and various [other] testing. By looking at all the affected organs, you reach a grade, and that can be mild, moderate, or severe [chronic GVHD].

How do you treat moderate-to-severe chronic GVHD at initial presentation and in the second line?

First-line treatment for chronic GVHD are steroids. For second line, there are many agents [to consider]. Ive tried most of them. I like photopheresis because its not pharmacological, but its pretty involved. Your patient will need a permanent catheter, and they will need to come to the transplant center twice a week, and you see a response after a long time. It takes an average of 50 photopheresis sessions for a response. But the beauty of photopheresis [is that] you could try it with other agents, so its not mutually exclusive. You could use it with ruxolitinib, ibrutinib, or any other agents.

The answer will be ibrutinib [for chronic GVHD], and thats based on the [results of a] phase 2 clinical trial that treated 42 patients with steroid-refractory chronic GVHD, and the efficacy was 69% [best overall response rate], and 31% complete response rate.3

What do you think of these poll results?

Everybody agrees on giving ibrutinib. When I gave this talk a couple months ago, lenalidomide [Revlimid] was not included in the poll. I added it because [recently], a nice study in Blood came out from the National Institutes of Health where they tried lenalidomide at a small dose, 2 mg, in steroid-refractory chronic GVHD. Its a large trial; I think its about 100 patients. Theyve seen responses that are comparable with ibrutinib....I treated a patient for multiple myeloma; he received a transplant for multiple myeloma, and now, 6 months later, he has chronic GVHD and some clonal plasma cells. So for him, I was comforted to know the results of the lenalidomide trial.

How does ruxolitinib play a role in this setting?

Ruxolitinib was reported in the REACH3 trial [NCT03112603] with very good responses in chronic GVHD.4 I think it probably will get approved for that indication. Looking at this study about 2 years ago, nothing was studied well in this indication, and ibrutinib was approved.

REACH3 was a large trial, almost 300 patients, and everybody was randomized to ruxolitinib 10 mg twice a day versus best available treatment. They looked at everybody about 6 months later for response.

What should physicians keep in mind when treating?

Chronic GvHD is pretty involved. Your patients will need a multidisciplinary approach. You need to pay attention to their bones. In the first 100 days post transplant, the average bone aging is 17 years.

So although were trying to treat acute GVHD, viruses, and prevent relapses, [by putting] your patients on some steroids, you are aging your patients bones by 17 years only in the first 100 days. No matter what you do, give your patients vitamin D, calcium, and Fosamax [alendronate sodium].

See the original post:
Gergis Explains the Differences Between Acute and Chronic GVHD - Targeted Oncology

To Read More: Gergis Explains the Differences Between Acute and Chronic GVHD – Targeted Oncology
categoriaSkin Stem Cells commentoComments Off on Gergis Explains the Differences Between Acute and Chronic GVHD – Targeted Oncology | dataFebruary 17th, 2021
Read All

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides a Corporate Update

By Dr. Matthew Watson

First Investigational New Drug (IND) application cleared for NX-2127 in patients with relapsed and refractory B-cell malignancies

Read the rest here:
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides a Corporate Update

To Read More: Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides a Corporate Update
categoriaGlobal News Feed commentoComments Off on Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides a Corporate Update | dataFebruary 17th, 2021
Read All

Lumos Pharma Announces Changes to its Board of Directors

By Dr. Matthew Watson

Lumos Pharma appoints new Board member, An van Es-Johansson, M.D., with wealth of experience in rare diseases Lumos Pharma appoints new Board member, An van Es-Johansson, M.D., with wealth of experience in rare diseases

Visit link:
Lumos Pharma Announces Changes to its Board of Directors

To Read More: Lumos Pharma Announces Changes to its Board of Directors
categoriaGlobal News Feed commentoComments Off on Lumos Pharma Announces Changes to its Board of Directors | dataFebruary 17th, 2021
Read All

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

By Dr. Matthew Watson

- More than 20 patients have been dosed with CTX001™ across CLIMB-Thal-111 and CLIMB-SCD-121 to date; completion of enrollment in both trials is expected in 2021 -

Go here to read the rest:
CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

To Read More: CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
categoriaGlobal News Feed commentoComments Off on CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results | dataFebruary 17th, 2021
Read All

Study Highlights Potential Clinical Value of ePlex® Blood Culture ID Panels

By Dr. Matthew Watson

Major teaching hospital in Grenoble, France demonstrates that ePlex BCID results could have modified antimicrobial treatment in 45% of patients Major teaching hospital in Grenoble, France demonstrates that ePlex BCID results could have modified antimicrobial treatment in 45% of patients

Read the original post:
Study Highlights Potential Clinical Value of ePlex® Blood Culture ID Panels

To Read More: Study Highlights Potential Clinical Value of ePlex® Blood Culture ID Panels
categoriaGlobal News Feed commentoComments Off on Study Highlights Potential Clinical Value of ePlex® Blood Culture ID Panels | dataFebruary 17th, 2021
Read All

Arcutis Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

By Dr. Matthew Watson

WESTLAKE VILLAGE, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today reported financial results for the quarter and year ended December 31, 2020, and provided a business update.

The rest is here:
Arcutis Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

To Read More: Arcutis Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
categoriaGlobal News Feed commentoComments Off on Arcutis Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update | dataFebruary 17th, 2021
Read All

Morphic Therapeutic to Participate in GI/Microbiome Panel Discussion at the 41st Annual Cowen Health Care Conference

By Dr. Matthew Watson

WALTHAM, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., president and chief executive officer of Morphic Therapeutic, is scheduled to participate in a panel discussion on the gastrointestinal microbiome at the 41st Annual Cowen Health Care Conference. The panel discussion will take place at 11:10 AM ET on Tuesday, March 2, 2021.

Read the original here:
Morphic Therapeutic to Participate in GI/Microbiome Panel Discussion at the 41st Annual Cowen Health Care Conference

To Read More: Morphic Therapeutic to Participate in GI/Microbiome Panel Discussion at the 41st Annual Cowen Health Care Conference
categoriaGlobal News Feed commentoComments Off on Morphic Therapeutic to Participate in GI/Microbiome Panel Discussion at the 41st Annual Cowen Health Care Conference | dataFebruary 17th, 2021
Read All

Eton Pharmaceuticals to Participate in 10th Annual SVB Leerink Global Healthcare Conference

By Dr. Matthew Watson

DEER PARK, Ill., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today announced that company management will be participating in the 10th Annual SVB Leerink Global Healthcare Conference from February 24th through February 26th.

Follow this link:
Eton Pharmaceuticals to Participate in 10th Annual SVB Leerink Global Healthcare Conference

To Read More: Eton Pharmaceuticals to Participate in 10th Annual SVB Leerink Global Healthcare Conference
categoriaGlobal News Feed commentoComments Off on Eton Pharmaceuticals to Participate in 10th Annual SVB Leerink Global Healthcare Conference | dataFebruary 17th, 2021
Read All

Myriad Genetics to Announce December 2020 Quarterly Financial Results on February 23, 2021

By Dr. Matthew Watson

SALT LAKE CITY, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced that it will hold its quarterly earnings conference call for the period ending December 30, 2020 with investors and analysts at 4:30 p.m. EST on Tuesday, February 23, 2021. During the call, Paul J. Diaz, president and CEO, and R. Bryan Riggsbee, Chief Financial Officer, will provide a financial overview and business update of Myriad’s performance for the quarter.

See the article here:
Myriad Genetics to Announce December 2020 Quarterly Financial Results on February 23, 2021

To Read More: Myriad Genetics to Announce December 2020 Quarterly Financial Results on February 23, 2021
categoriaGlobal News Feed commentoComments Off on Myriad Genetics to Announce December 2020 Quarterly Financial Results on February 23, 2021 | dataFebruary 17th, 2021
Read All

MediWound to Report Fourth Quarter and Fiscal 2020 Financial Results and Host a Conference Call and Webcast on February 25, 2021

By Dr. Matthew Watson

YAVNE, Israel, Feb. 16, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced that the Company will release its financial results for the fourth quarter and year ended December 31, 2020 at 7:00 am Eastern Time on Thursday, February 25, 2021.

Read more:
MediWound to Report Fourth Quarter and Fiscal 2020 Financial Results and Host a Conference Call and Webcast on February 25, 2021

To Read More: MediWound to Report Fourth Quarter and Fiscal 2020 Financial Results and Host a Conference Call and Webcast on February 25, 2021
categoriaGlobal News Feed commentoComments Off on MediWound to Report Fourth Quarter and Fiscal 2020 Financial Results and Host a Conference Call and Webcast on February 25, 2021 | dataFebruary 17th, 2021
Read All

Aleafia Health Announces $15 Million Bought Deal Offering of Units

By Dr. Matthew Watson

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

More here:
Aleafia Health Announces $15 Million Bought Deal Offering of Units

To Read More: Aleafia Health Announces $15 Million Bought Deal Offering of Units
categoriaGlobal News Feed commentoComments Off on Aleafia Health Announces $15 Million Bought Deal Offering of Units | dataFebruary 17th, 2021
Read All

Travere Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results

By Dr. Matthew Watson

SAN DIEGO, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2020 financial results on Monday, March 1, 2021 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.

Here is the original post:
Travere Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results

To Read More: Travere Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results
categoriaGlobal News Feed commentoComments Off on Travere Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results | dataFebruary 17th, 2021
Read All

ProQR Announces Expert Perspectives Call on Disease Education and Endpoints in Usher Syndrome

By Dr. Matthew Watson

LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced that the Company will host an Expert Perspectives call on February 22, 2021 at 12:00pm EST. The call will feature a discussion between Aniz Girach, MD, Chief Medical Officer of ProQR Therapeutics and Paul Yang, MD, PhD about disease education and endpoints in Usher syndrome and non-syndromic Retinitis Pigmentosa (nsRP).  Areas of focus for the session will include which vision measures are most informative in the context of this disease setting, the role of patient baseline and disease progression, and an overview of the objectives of the Phase 1/2 Stellar trial of QR-421a.

View post:
ProQR Announces Expert Perspectives Call on Disease Education and Endpoints in Usher Syndrome

To Read More: ProQR Announces Expert Perspectives Call on Disease Education and Endpoints in Usher Syndrome
categoriaGlobal News Feed commentoComments Off on ProQR Announces Expert Perspectives Call on Disease Education and Endpoints in Usher Syndrome | dataFebruary 17th, 2021
Read All

Medexus to Present at the Winter Wonderland Conference- Best Ideas from the Buy-Side

By Dr. Matthew Watson

TORONTO, CHICAGO and MONTREAL, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced today that it will be presenting at the Winter Wonderland Conference, hosted by The MicroCap Rodeo, being held virtually on February 16th – February 19th, 2021.

View original post here:
Medexus to Present at the Winter Wonderland Conference- Best Ideas from the Buy-Side

To Read More: Medexus to Present at the Winter Wonderland Conference- Best Ideas from the Buy-Side
categoriaGlobal News Feed commentoComments Off on Medexus to Present at the Winter Wonderland Conference- Best Ideas from the Buy-Side | dataFebruary 17th, 2021
Read All

Wave Life Sciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference  

By Dr. Matthew Watson

CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the virtual 10th Annual SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 5:00 p.m. ET.

Here is the original post:
Wave Life Sciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference  

To Read More: Wave Life Sciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference  
categoriaGlobal News Feed commentoComments Off on Wave Life Sciences to Present at the 10th Annual SVB Leerink Global Healthcare Conference   | dataFebruary 17th, 2021
Read All

GenMark Diagnostics to Participate in the Cowen 41st Annual Health Care Conference

By Dr. Matthew Watson

CARLSBAD, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in the upcoming Cowen 41st Annual Health Care Conference.

Read the original post:
GenMark Diagnostics to Participate in the Cowen 41st Annual Health Care Conference

To Read More: GenMark Diagnostics to Participate in the Cowen 41st Annual Health Care Conference
categoriaGlobal News Feed commentoComments Off on GenMark Diagnostics to Participate in the Cowen 41st Annual Health Care Conference | dataFebruary 17th, 2021
Read All

Innate Pharma to Participate in the 10th Annual SVB Leerink Global Healthcare Conference

By Dr. Matthew Watson

MARSEILLE, France, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that members of its senior management team are scheduled to participate in the following upcoming virtual investor conference:

Excerpt from:
Innate Pharma to Participate in the 10th Annual SVB Leerink Global Healthcare Conference

To Read More: Innate Pharma to Participate in the 10th Annual SVB Leerink Global Healthcare Conference
categoriaGlobal News Feed commentoComments Off on Innate Pharma to Participate in the 10th Annual SVB Leerink Global Healthcare Conference | dataFebruary 17th, 2021
Read All

Addex Provides Trading Update and Completes 2020 with Strong Cash Position of CHF18.7 million

By Dr. Matthew Watson

Geneva, Switzerland, February 17, 2021 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it completed 2020 with a strong cash position of CHF18.7 million of cash and cash equivalents.

Continued here:
Addex Provides Trading Update and Completes 2020 with Strong Cash Position of CHF18.7 million

To Read More: Addex Provides Trading Update and Completes 2020 with Strong Cash Position of CHF18.7 million
categoriaGlobal News Feed commentoComments Off on Addex Provides Trading Update and Completes 2020 with Strong Cash Position of CHF18.7 million | dataFebruary 17th, 2021
Read All

ObsEva to Present at the SVB Leerink 10th Annual Global Healthcare Conference

By Dr. Matthew Watson

Continued here:
ObsEva to Present at the SVB Leerink 10th Annual Global Healthcare Conference

To Read More: ObsEva to Present at the SVB Leerink 10th Annual Global Healthcare Conference
categoriaGlobal News Feed commentoComments Off on ObsEva to Present at the SVB Leerink 10th Annual Global Healthcare Conference | dataFebruary 17th, 2021
Read All

Novartis and the Bill & Melinda Gates Foundation collaborate to discover and develop an accessible in vivo gene therapy for sickle cell disease

By Dr. Matthew Watson

Basel, February 17, 2021 — Novartis today announced that it has entered into a grant agreement with the Bill & Melinda Gates Foundation. As part of the agreement, the foundation will provide funding support for the discovery and development of a single-administration, in vivo gene therapy to cure sickle cell disease (SCD). The project brings together Novartis drug discovery and gene therapy expertise with the Gates Foundation’s charitable objectives to expand access to healthcare in low-resource settings in an effort to address this potentially life-threatening genetic disease.

See the article here:
Novartis and the Bill & Melinda Gates Foundation collaborate to discover and develop an accessible in vivo gene therapy for sickle cell disease

To Read More: Novartis and the Bill & Melinda Gates Foundation collaborate to discover and develop an accessible in vivo gene therapy for sickle cell disease
categoriaGlobal News Feed commentoComments Off on Novartis and the Bill & Melinda Gates Foundation collaborate to discover and develop an accessible in vivo gene therapy for sickle cell disease | dataFebruary 17th, 2021
Read All

Page 3«..2345..1020..»